ECSP19082184A - Anticuerpos agonistas contra btla y sus usos - Google Patents
Anticuerpos agonistas contra btla y sus usosInfo
- Publication number
- ECSP19082184A ECSP19082184A ECSENADI201982184A ECDI201982184A ECSP19082184A EC SP19082184 A ECSP19082184 A EC SP19082184A EC SENADI201982184 A ECSENADI201982184 A EC SENADI201982184A EC DI201982184 A ECDI201982184 A EC DI201982184A EC SP19082184 A ECSP19082184 A EC SP19082184A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibodies against
- agonist antibodies
- btla
- against btla
- antibodies
- Prior art date
Links
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 title abstract 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan anticuerpos que se fijan a BTLA, y métodos para usarlos, en donde dichos anticuerpos son útiles como agentes para tratar afecciones asociadas a la enfermedad autoinmunitaria, que incluyen el tratamiento de lupus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508510P | 2017-05-19 | 2017-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19082184A true ECSP19082184A (es) | 2019-11-30 |
Family
ID=62245543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201982184A ECSP19082184A (es) | 2017-05-19 | 2019-11-18 | Anticuerpos agonistas contra btla y sus usos |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10604573B2 (es) |
| EP (1) | EP3625257A1 (es) |
| JP (2) | JP6790304B2 (es) |
| KR (3) | KR20220158847A (es) |
| CN (3) | CN117402244A (es) |
| AR (1) | AR111752A1 (es) |
| AU (2) | AU2018269585B2 (es) |
| BR (1) | BR112019021547A2 (es) |
| CA (2) | CA3184628A1 (es) |
| CL (1) | CL2019003215A1 (es) |
| CO (1) | CO2019012756A2 (es) |
| CR (1) | CR20190521A (es) |
| DO (1) | DOP2019000293A (es) |
| EA (1) | EA201992460A1 (es) |
| EC (1) | ECSP19082184A (es) |
| JO (1) | JOP20190261A1 (es) |
| MA (1) | MA49133A (es) |
| MX (1) | MX381033B (es) |
| MY (2) | MY198277A (es) |
| NZ (1) | NZ758360A (es) |
| PE (1) | PE20191843A1 (es) |
| PH (1) | PH12019502575A1 (es) |
| SA (1) | SA519410534B1 (es) |
| TW (4) | TWI804044B (es) |
| WO (1) | WO2018213113A1 (es) |
| ZA (1) | ZA201906954B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| CN114555792A (zh) | 2019-10-15 | 2022-05-27 | 伊莱利利公司 | 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系 |
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| KR20230096024A (ko) * | 2020-10-23 | 2023-06-29 | 아납티스바이오, 아이엔씨. | B 및 t 림프구 약화인자 (btla) 조절제 및 이의 사용 방법 |
| AU2023213914A1 (en) * | 2022-01-29 | 2024-08-15 | Hifibio, Inc. | Anti-btla antibodies and uses thereof in treating cancer |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024243594A1 (en) * | 2023-05-25 | 2024-11-28 | Anaptysbio, Inc. | Btla agonist for mudulation of dendritic cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546541B2 (en) | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
| JP2006515167A (ja) * | 2002-10-25 | 2006-05-25 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための新規組成物と方法 |
| CA2669921A1 (en) * | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to btla and methods of use |
| CN102762593B (zh) * | 2009-07-31 | 2015-05-20 | 梅达雷克斯有限责任公司 | 抗btla的完全人抗体 |
| US9533039B2 (en) * | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| WO2014018931A1 (en) * | 2012-07-26 | 2014-01-30 | The General Hospital Corporation | Methods and compositions for treating autoimmune disease |
| US10005839B2 (en) * | 2013-05-17 | 2018-06-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antagonist of the BTLA/HVEM interaction for use in therapy |
| US11352428B2 (en) * | 2015-04-29 | 2022-06-07 | Sanford Burnham Prebys Medical Discovery Institute | Modulation of immune response using BTLA agonist antibodies |
| EP3383908A1 (en) * | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
-
2017
- 2017-06-16 JO JOP/2019/0261A patent/JOP20190261A1/ar unknown
-
2018
- 2018-05-03 AR ARP180101158A patent/AR111752A1/es not_active Application Discontinuation
- 2018-05-04 TW TW110141711A patent/TWI804044B/zh active
- 2018-05-04 TW TW112116965A patent/TW202334237A/zh unknown
- 2018-05-04 TW TW107115166A patent/TWI677504B/zh not_active IP Right Cessation
- 2018-05-04 TW TW108133289A patent/TWI747043B/zh not_active IP Right Cessation
- 2018-05-11 US US15/977,003 patent/US10604573B2/en active Active
- 2018-05-11 CA CA3184628A patent/CA3184628A1/en active Pending
- 2018-05-11 CN CN202311364321.5A patent/CN117402244A/zh active Pending
- 2018-05-11 MY MYPI2021007625A patent/MY198277A/en unknown
- 2018-05-11 AU AU2018269585A patent/AU2018269585B2/en active Active
- 2018-05-11 MY MYPI2019006702A patent/MY197425A/en unknown
- 2018-05-11 CN CN201880033180.XA patent/CN110621699B/zh active Active
- 2018-05-11 NZ NZ758360A patent/NZ758360A/en not_active IP Right Cessation
- 2018-05-11 CA CA3064518A patent/CA3064518A1/en active Pending
- 2018-05-11 MA MA049133A patent/MA49133A/fr unknown
- 2018-05-11 BR BR112019021547-6A patent/BR112019021547A2/pt unknown
- 2018-05-11 PE PE2019002417A patent/PE20191843A1/es unknown
- 2018-05-11 MX MX2019013604A patent/MX381033B/es unknown
- 2018-05-11 KR KR1020227039792A patent/KR20220158847A/ko not_active Ceased
- 2018-05-11 WO PCT/US2018/032218 patent/WO2018213113A1/en not_active Ceased
- 2018-05-11 KR KR1020197033639A patent/KR102294051B1/ko active Active
- 2018-05-11 EA EA201992460A patent/EA201992460A1/ru unknown
- 2018-05-11 JP JP2020511876A patent/JP6790304B2/ja active Active
- 2018-05-11 CR CR20190521A patent/CR20190521A/es unknown
- 2018-05-11 KR KR1020217026470A patent/KR20210106033A/ko not_active Ceased
- 2018-05-11 CN CN202311364322.XA patent/CN117402245A/zh active Pending
- 2018-05-11 EP EP18727622.5A patent/EP3625257A1/en active Pending
-
2019
- 2019-10-22 ZA ZA2019/06954A patent/ZA201906954B/en unknown
- 2019-11-08 CL CL2019003215A patent/CL2019003215A1/es unknown
- 2019-11-12 SA SA519410534A patent/SA519410534B1/ar unknown
- 2019-11-15 CO CONC2019/0012756A patent/CO2019012756A2/es unknown
- 2019-11-15 DO DO2019000293A patent/DOP2019000293A/es unknown
- 2019-11-18 PH PH12019502575A patent/PH12019502575A1/en unknown
- 2019-11-18 EC ECSENADI201982184A patent/ECSP19082184A/es unknown
-
2020
- 2020-02-17 US US16/792,396 patent/US11396545B2/en active Active
- 2020-11-04 JP JP2020184527A patent/JP7072622B2/ja active Active
-
2021
- 2021-12-02 AU AU2021277743A patent/AU2021277743A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19082184A (es) | Anticuerpos agonistas contra btla y sus usos | |
| CR20190179A (es) | Anticuerpos anti-il-33 y usos de estos | |
| UY35417A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| CO2017002719A2 (es) | Anticuerpos anti-glucagón | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| ECSP17070399A (es) | Anticuerpos contra icos | |
| SV2017005355A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| PE20171556A1 (es) | Agentes de union a cd123 y usos de estos | |
| EA201891376A1 (ru) | Бензотиофеновые селективные блокаторы эстрогеновых рецепторов | |
| MX2019000641A (es) | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. | |
| NI201800134A (es) | Anticuerpos antifactor de la coagulación xi | |
| BR112017006520A2 (pt) | métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28 | |
| BR112018067951A2 (pt) | moléculas que se ligam a ilt7 e métodos de uso destas | |
| UY35327A (es) | ?4,5-dihidro-1,2,4-oxadiazoles disustituidos en 3,5 y composiciones y métodos para controlar plagas de nematodos?. | |
| AR106133A1 (es) | Métodos para el tratamiento de la epilepsia | |
| MX2016016664A (es) | Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r). | |
| AR129996A2 (es) | Anticuerpos dirigidos contra il-33 y sus usos | |
| DOP2019000082A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| ECSP17039183A (es) | Agonistas parciales del receptor de insulina | |
| AR098780A1 (es) | Proceso de obtención de micropartículas de quitosano | |
| AR103227A1 (es) | Anticuerpos anti-csf1r para el tratamiento de svp | |
| AR105316A1 (es) | Anticuerpos contra el receptor de transferrina (anti-cd71), anticuerpos anti-cd71 activables y sus métodos de uso |